Prostate Cancer Statistics 2026, From Cases to Survival
Prostate cancer statistics for 2026 show a 1 in 8 lifetime risk — but only 1 in 44 men die of it. Here's what the latest US numbers really mean.
Understanding Your Prostate Cancer Survival Rate by Stage
Prostate cancer survival rates vary by stage — from over 99% for localized disease to 38% once it spreads. Here's what the numbers mean for you.
Understanding the Outlook With Metastatic Prostate Cancer
Metastatic prostate cancer has a 38% 5-year survival rate—but that average doesn't predict any one person's outlook. Here's how to read it.
Reading the Early Signs of Prostate Cancer Recurrence
Prostate cancer recurrence usually shows up first as a rising PSA — not symptoms. Here's how doctors read the threshold, doubling time, and PSMA PET scans.
What to Know About Urinary Incontinence After Prostatectomy
Leaking urine after prostatectomy is expected — and usually temporary. Here's the honest recovery timeline, from catheter removal to the 12-month mark.
How to Manage Erectile Dysfunction After Prostate Cancer
Erectile dysfunction after prostate cancer is common but often manageable — and recovery odds rise sharply for younger men with nerve-sparing surgery.
How Doctors Choose Between Prostate Cancer Surgery and Radiation
Choosing between prostate cancer surgery and radiation? Survival is nearly the same for both—what differs is the side-effect trade-off.
PARP Inhibitors for BRCA-Linked Prostate Cancer Explained
PARP inhibitors work only against prostate cancers with BRCA or HRR mutations—a December 2025 FDA approval added a BRCA2 hormone-sensitive option.
A Clear Look at Immunotherapy for Prostate Cancer and Provenge
Immunotherapy for prostate cancer works differently than chemo: Provenge may extend survival even when scans don't shrink. Here's what that means for you.
How Pluvicto and Lutetium-177 Work in Prostate Cancer
Pluvicto, a lutetium-177 radioligand therapy, targets PSMA-positive metastatic prostate cancer — here's how it works and who qualifies.